Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Apellis (APLS) to $30 from $31 and keeps an Equal Weight rating on the shares following the Q4 report. The company’s product revenues were in-line with the results pre-announced in January, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Buy Rating for Apellis Pharmaceuticals Driven by Strategic Growth Initiatives and Strong Product Performance
- Hold Rating for Apellis Pharmaceuticals Amidst Market Challenges and Moderate Growth Expectations
- Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts
- Apellis Pharmaceuticals Reports Strong 2024 Growth
- Apellis Pharmaceuticals’ Earnings Call Highlights Growth and Challenges